Studies related to IGF-1 and Ketogenic diet

A Ketogenic Diet Reduces Central Obesity And Serum Insulin In Women With Ovarian Or Endometrial Cancer

Effect Decrease
Values (ng/ml). Mean + SE. Ketogenic: before 120.3 ± 8.9, after 100.7 ± 9.6. Control: before 116 ± 13.7, after 111 ± 13.4.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 73
Sex Female
Notes for this study:
In a randomized, unblinded, controlled trial, 73 participants with ovarian or endometrial cancer were assigned to a ketogenic diet or a control diet for 12 weeks. The ketogenic diet was to be up to 5% of energy from carbohydrate, 25% from protein, and 70% from fat. The control diet was the ACS diet, and the goal was to increase fiber, antioxidants, sugars, and saturated fat. Participants were educated about the diets, and adherence was measured through urinary ketone testing.

80% of the participants in the ketogenic group tested positive for ketosis during the trial. The ketogenic diet led to significantly greater fat loss, visceral fat loss, and nonsignificantly greater lean mass loss. The ketogenic group saw a significantly greater reduction in insulin and c-peptide, and a nonsignificantly greater reduction in IGF-1 and fasting glucose.

Full details on all 2 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.